Details of Disease

Disease Name

Urinary incontinence

Disease Class

MF50: Abnormal micturition

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DIS3U12J: Urinary incontinence

ICD-11

ICD-11: MF50.2

Disease Identifiers

MONDO ID

MONDO_0004745

MESH ID

D011317

UMLS CUI

C0033117

MedGen ID

19462

HPO ID

HP:0200023

Orphanet ID

140949

SNOMED CT ID

6273006

General Information of Disease (ID: DIS3U12J)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Disopyramide	DM5SYZP	Approved	Small molecular drug	[1]
Emepronium	DMCOAVT	Approved	Small molecular drug	[2]
Oxybutynin hydrochloride	DMF2KLU	Approved	Small molecular drug	[2]
Propiverine	DMUWBIJ	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DR-3001	DMGOBUK	Phase 3	NA	[3]
Terodiline	DM4MZXE	Phase 3	Small molecular drug	[4]
(S)-oxybutynin	DMAV426	Phase 2	NA	[5]
FP-1097	DMC1F2T	Phase 2	NA	[6]
GW-427353	DMBX9C0	Phase 2	Small molecular drug	[7]
SSR240600	DMVZ01T	Phase 2	Small molecular drug	[8]
UISH-001	DMFUMYD	Phase 1/2	NA	[9]
NS-8	DMX8LY4	Phase 1	Small molecular drug	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 21 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Zamifenacin	DM51FVE	Discontinued in Phase 3	Small molecular drug	[11]
Dabuzalgron	DMDQH5E	Discontinued in Phase 2	Small molecular drug	[12]
DDP-200	DMMV6RK	Discontinued in Phase 2	NA	[13]
KW-7158	DMJNSML	Discontinued in Phase 2	Small molecular drug	[14]
NS-49	DMQ8P4U	Discontinued in Phase 2	Small molecular drug	[15]
REC-15/3079	DMIEFH0	Discontinued in Phase 2	Small molecular drug	[16]
RO-26-9228	DMPB80O	Discontinued in Phase 2	Small molecular drug	[17]
SL-25.1039	DME1JYP	Discontinued in Phase 2	NA	[18]
SOU-001	DMPAEK5	Discontinued in Phase 2	NA	[19]
Terflavoxate	DM4K3P9	Discontinued in Phase 2	Small molecular drug	[20]
ZD-6169	DMVBL25	Discontinued in Phase 2	Small molecular drug	[21]
KN-203	DM37IH5	Discontinued in Phase 1	NA	[22]
MN-246	DM2PUYI	Discontinued in Phase 1	NA	[23]
OPC-51803	DMDCOSP	Discontinued in Phase 1	Small molecular drug	[24]
OX 19	DM5UYI7	Discontinued in Phase 1	NA	[25]
SR 144190	DMK4XT8	Discontinued in Phase 1	Small molecular drug	[26]
UK-224671	DMDTRJB	Discontinued in Phase 1	Small molecular drug	[27]
VNA-932	DMKRG0I	Discontinued in Phase 1	Small molecular drug	[28]
AZD-5106	DMABY43	Terminated	NA	[29]
F-992	DMJ3MAZ	Terminated	NA	[30]
UK-290795	DMQFSAB	Terminated	NA	[31]
------------------------------------------------------------------------------------


⏷ Show the Full List of 21 Drug(s)

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DPI-221	DME5S3C	Investigative	NA	[32]
MDDR 287569	DMZJPOB	Investigative	NA	[33]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7167).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	ClinicalTrials.gov (NCT00685113) A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT00002359) A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA)Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega. U.S. National Institutes of Health.
5	A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol. 2014 Apr;191(4):1014-21.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019662)
7	ClinicalTrials.gov (NCT00394186) A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS). U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT00174798) MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.. U.S. National Institutes of Health.
9	ClinicalTrials.gov (NCT01340066) Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence. U.S. National Institutes of Health.
10	Clinical pipeline report, company report or official report of Nippon Shinyaku Co Ltd.
11	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003650)
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3469).
13	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020170)
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013319)
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 481).
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 74).
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2785).
18	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014859)
19	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014478)
20	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003221)
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006442)
22	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307)
23	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022773)
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2173).
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021110)
26	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008589)
27	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010850)
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3537).
29	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015341)
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014040)
31	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017162)
32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
33	Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. Invest New Drugs. 2012 April; 30(2): 749-757.